128 related articles for article (PubMed ID: 37739030)
1. Accuracy of Cytologic vs Histologic Specimens for Assessment of Programmed Cell Death Ligand-1 Expression in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Tajarernmuang P; Aliaga F; Alwakeel AJ; Tavaziva G; Turner K; Menzies D; Wang H; Ofiara L; Benedetti A; Gonzalez AV
Chest; 2024 Feb; 165(2):461-474. PubMed ID: 37739030
[TBL] [Abstract][Full Text] [Related]
2. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN
J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671
[TBL] [Abstract][Full Text] [Related]
3. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
[TBL] [Abstract][Full Text] [Related]
4. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of programmed death ligand 1 expression in paired cytologic and histologic specimens of non-small cell lung cancer.
Daverio M; Patrucco F; Gavelli F; Airoldi C; Sciortino G; Chiaramonte C; Rena O; Balbo PE; Boldorini RL
Cancer Cytopathol; 2020 Aug; 128(8):580-588. PubMed ID: 32463583
[TBL] [Abstract][Full Text] [Related]
6. Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.
Koomen BM; van der Starre-Gaal J; Vonk JM; von der Thüsen JH; van der Meij JJC; Monkhorst K; Willems SM; Timens W; 't Hart NA
Cancer Cytopathol; 2021 Apr; 129(4):304-317. PubMed ID: 33108706
[TBL] [Abstract][Full Text] [Related]
7. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.
Mei P; Shilo K; Wei L; Shen R; Tonkovich D; Li Z
Cancer Cytopathol; 2019 Jul; 127(7):447-457. PubMed ID: 31025831
[TBL] [Abstract][Full Text] [Related]
8. Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients.
Kuempers C; van der Linde LIS; Reischl M; Vogel W; Stellmacher F; Reck M; Heigener D; Rabe KF; Kirfel J; Perner S; Welker L
Virchows Arch; 2020 Feb; 476(2):261-271. PubMed ID: 31392467
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
[TBL] [Abstract][Full Text] [Related]
10. Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.
Lou SK; Ko HM; Kinoshita T; MacDonald S; Weiss J; Czarnecka-Kujawa K; Boerner SL; Yasufuku K; Tsao MS; Schwock J
Acta Cytol; 2020; 64(6):577-587. PubMed ID: 32599583
[TBL] [Abstract][Full Text] [Related]
11. Cytology for PD-L1 testing: A systematic review.
Gosney JR; Boothman AM; Ratcliffe M; Kerr KM
Lung Cancer; 2020 Mar; 141():101-106. PubMed ID: 32007657
[TBL] [Abstract][Full Text] [Related]
12. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
Chauhan A; Siegel L; Freese R; Racila E; Stewart J; Amin K
Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
[TBL] [Abstract][Full Text] [Related]
13. Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens.
Sinclair W; Kobalka P; Ren R; Beshai B; Lott Limbach AA; Wei L; Mei P; Li Z
Diagn Cytopathol; 2021 Feb; 49(2):219-225. PubMed ID: 33104298
[TBL] [Abstract][Full Text] [Related]
14. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
15. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.
Russell-Goldman E; Kravets S; Dahlberg SE; Sholl LM; Vivero M
Cancer Cytopathol; 2018 Apr; 126(4):253-263. PubMed ID: 29405663
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC.
Lau SCM; Rabindranath M; Weiss J; Li JJN; Fung AS; Mullen D; Alshamlan N; Ruff HM; Tong LCB; Pal P; Cabanero MR; Hsu YR; Sacher AG; Shepherd FA; Liu G; Bradbury PA; Yasufuku K; Czarnecka-Kujawa K; Mi Ko H; Tsao MS; Leighl NB; Schwock J
Lung Cancer; 2022 Sep; 171():42-46. PubMed ID: 35907387
[TBL] [Abstract][Full Text] [Related]
18. Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx.
Skov BG; Skov T
Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):453-459. PubMed ID: 28549039
[TBL] [Abstract][Full Text] [Related]
19. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
20. A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens.
Bubendorf L; Conde E; Cappuzzo F; Langfort R; Schildhaus HU; Votruba J; Concha-López Á; Esteban-Rodriguez I; Feng J; Devenport J; Boyiddle C; Morris S; Trunzer K; Kerr KM
Cancer Cytopathol; 2020 Dec; 128(12):928-938. PubMed ID: 32721105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
